What one share of Curanex Pharmaceuticals holds
If the Phase I trial is completed with positive results, we intend to proceed with a Phase II trial for ulcerative colitis as our lead indication.
Curanex Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.38 |
|---|---|
| Cash and investments | $0.10 |
| Book value | $0.17 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$0.03 | — | — | — | $0.02 |
| 2025 | — | −$0.17 | — | — | — | $0.40 |
Common questions about Curanex Pharmaceuticals
How much does one share of Curanex Pharmaceuticals earn?
Over the last 12 months, Curanex Pharmaceuticals lost $0.38 for each share.
Does Curanex Pharmaceuticals pay a dividend?
Curanex Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Curanex Pharmaceuticals’s book value per share?
Curanex Pharmaceuticals’s book value is $0.17 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Curanex Pharmaceuticals have?
Each share of Curanex Pharmaceuticals has $0.10 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.